Due to a system-wide technology update, we are experiencing extremely high call volume. We appreciate your patience with our operators during this time. Thank you for choosing Fox Chase Cancer Center.
Jeffrey Farma Appointed to Committee Leadership Role within the Society of Surgical Oncology
PHILADELPHIA (May 17, 2018) – Jeffrey M. Farma, MD, FACS, associate professor of surgical oncology at Fox Chase Cancer Center, has been appointed vice chair of the Complex General Surgical Oncology Program Directors Committee of the Society of Surgical Oncology (SSO). Farma has been a member of the committee for the past five years in his capacity as director of the Surgical Oncology Fellowship Training Program at Fox Chase.
The one-year term as vice chair provides Farma a leadership role within SSO, in which he will help to unify the directors of surgical oncology fellowship programs, improve the training curriculum, and address issues related to fellowship training. He will also represent the group at medical meetings, such as the SSO Annual Cancer Symposium and the American College of Surgeons’ Annual Clinical Congress.
Farma joined Fox Chase in 2009 as an attending surgeon in the Department of Surgery. He completed his clinical surgical oncology fellowship at Moffitt Cancer Center in Tampa, and his residency in general surgery at Temple University Hospital. He also completed a surgical oncology fellowship at the National Cancer Institute. He specializes in treating colorectal cancer, melanoma, sarcoma, and minimally invasive and robotic surgery.
SSO is the premier international organization for surgeons and health care providers dedicated to improving multidisciplinary patient care by advancing the science, education, and practice of cancer surgery.
“This appointment will allow me to contribute to the advancement of surgical oncology education, which is an area of particular interest. As a longtime member of SSO, I am honored to serve as vice chair of the committee,” said Farma.
Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence five consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.
For more information, call 888-369-2427